Picture of Augmedix logo

AUGX — Augmedix News Story

0.000.00%
us flag iconLast trade - 00:00
IndustrialsSpeculativeSmall CapSucker Stock

Augmedix Inc expected to post a loss of 13 cents a share - Earnings Preview

* Augmedix Inc  AUGX.OQ   AUGX.O  is expected to show a rise
in
quarterly revenue when it reports  results on May 13 for the
period ending January 1 0001
    * The San Francisco California-based  company is expected to
report a 38.8% increase in revenue to $13.367 million from $9.63
million a year ago, according to the mean estimate from 6
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Augmedix Inc is for a
loss
of 13 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 4.8%
in the last three months. ​
    * Wall Street's median 12-month price target for Augmedix
Inc is
$5.70​, above​ its last closing price of $2.23. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jan. 1 0001   -0.10       -0.10      -0.09     Beat    10
 Sep. 30 0001  -0.11       -0.12      -0.10     Beat    14.9
 Jun. 30 2023  -0.13       -0.13      -0.12     Beat    7.7​
 Mar. 31 2023  -0.15       -0.15      -0.14     Beat    8.2
 ​​Jan.        -0.15       -0.15      -0.15     Met     2.2
 1 0001                                                 
 Sep. 30 2022              -0.17                        ​
 Jun. 30 2022  -0.16       -0.15      -0.20     Missed  -29
 Mar. 31 2022  -0.15       -0.15      -0.16     Missed  -4.9
 This summary was machine generated May 10 at 22:17 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Augmedix

See all news